Posts tagged “Quintiles”

May 3

QuintilesIMS earnings top Street expectations

QuintilesIMS   QuintilesIMS, the life science services giant that maintains headquarters in Durham and Danbury, Ct., reported earnings for the first quarter Wednesday that beat Wall Street expectations.

April 24

Premium Lock QuintilesIMS, Salesforce form 'molecule to market' data alliance

QuintilesIMS   QuintilesIMS is partnering with Salesforce to utilize cloud technology for what it calls a "molecule to market" data shop for pharmaceutical companies.

March 22

Premium Lock Novan hires former Quintiles exec to lead product development; CFO leaves

Novan is expanding its management team with a new chief development officer position. The company, which went public last year, also is looking for a new chief financial officer.

Novan Novan

Updated February 27

Premium Lock Former Quintiles CEO Pike received $20.6M in compensation in 2016

​Former Quintiles chief executive Tom Pike received $20.6 million in compensation following his post-acquisition departure from the Durham-based clinical research company in late 2016, according to a filing with the Securities and Exchange Commission.

Tom Pike    Tom Pike

Updated February 24

Premium Lock Life science giant battle continues: QuintilesIMS raising $1.5B; LabCorp acquires labs group

QuintilesIMS   A pair of life science giants - and rivals - are making moves. QuintilesIMS is raising nearly $1.5 billion in capital, perhaps in part for future acquisitions. Meanwhile, LabCorp makes a buy to expand its services network.

February 16

Premium Lock QuintilesIMS, ABB, IBM, Cisco crack 'Most Admired Companies' list

Fortune Life science giant QuintilesIMS and several other companies with a major presence in the Triangle are among the firms cracking the latest "World's Most Admired Companies" list from Fortune.

Updated February 14

Premium Lock QuintilesIMs reports $178M loss in first post-merger quarter

QuintilesIMS   QuintilesIMS, the life science giant that emerged from the October merger of Durham-based Quintiles and IMS, reported a $178 million quarterly loss for its first three months as one company.

January 26

Premium Lock As 'Trump bump' lifts Dow to 20K, many Triangle tech stocks join party

Bullish     The Dow hit the 20,000 mark Wednesday, and other Street benchmarks are at record levels as well as the post-election "Trump bump" continues. Several Triangle tech stocks have joined the surge, but management changes at Quintiles and Red Hat show not even Donald Trump means every stock rises.

December 15, 2016

Premium Lock 2016 Roundup: NC Biotech sector continued to grow

Biotech      North Carolina's life science sector registered another year of robust growth in 2016. The NC Biotech Center offers this roundup of expansions, mergers, and deals in the state biotech industry.

Updated November 30, 2016

Premium Lock Tom Pike giving up millions of dollars in quitting QuintilesIMS

Tom Pike is walking away from millions of dollars in stock and bonuses as he retires "effective immediately" from QuintilesIMS. The former Quintiles CEO, who stepped aside as part of a $17 billion merger with IMS, could have made more than $17 million if he had stayed with the life science giant through 2017. Pike isn't talking, according to the company.

Tom Pike and Dennis Gillings (center) ring in NYSE action Tom Pike and Dennis Gillings (center) ring in NYSE action

Updated November 30, 2016

Premium Lock Former Quintiles CEO Tom Pike to retire in wake of IMS merger

Tom Pike, the CEO who led Quintiles to a multi-billion dollar merger earlier this year with IMS and accepted a demotion as part of the deal, is retiring.

Tom Pike, left, banters with Jim Cramer Tom Pike, left, banters with Jim Cramer

November 2, 2016

Premium Lock QuintilesIMS plans $1.5B stock buyback through 2017

QuintilesIMS   QuintilesIMS is the result of a recently completed merger between Quintiles Transnational Holdings Inc. and IMS Health Holdings Inc. The companies reported separate third quarter results. And one of its first acts is a plan to repurchase $1.5 billion worth of shares by the end of 2017,

October 28, 2016

Premium Lock New report shows growing impact of genetics, data in fighting disease

Over the past two decades, an explosion in biomarker and genomic research has enabled the life science industry to develop 71 drugs that target cancer, according to a new report from the QuintilesIMS Institute. The development of personalized treatment based on genetic information is one example of data's growing importance to improving human health, the report says.

Fighting disease with genetics Fighting disease with genetics

Updated October 3, 2016

Premium Lock Quintiles, IMS Health complete $17B merger; no word on any job cuts

Quintiles has a new name: Quintiles IMS Holdings Inc. after the multi-billion-dollar merger between the two life science companies was officially wrapped up Monday morning. Will there be layoffs? That's note clear right now.

Updated October 3, 2016

Premium Lock QuintilesIMS management scorecard: IMS 8, Quintiles 11 but ...

In the $17 billion "merger of equals" between Quintiles and IMS Health, the new QuintilesIMS management tilts to IMS at the highest of three levels but the old Quintiles nabs well over half of the next two executive suite tiers.

Tom Pike    Tom Pike

Updated September 20, 2016

Premium Lock LabCorp names former Quintiles exec to lead Covance

John Ratliff, who resigned as president of Quintiles for "personal reasons" in 2013, is taking over as CEO of Covance Drug Development, which is now owned by LabCorp.

John Ratliff John Ratliff

Updated August 29, 2016

Premium Lock Quintiles CEO to take vice chair role in Q-IMS Health merger

Tom Pike    IMS Health Holdings will own a majority of shares if and when a proposed merger with Quintiles wins regulatory approval. And that ownership is shown in the lineup of the proposed executive lineup for a new company as Quintiles CEO Tom Pike takes on a lesser role.

August 29, 2016

Premium Lock Quintiles' COO, 2 board members to leave as Q, IMS Health merge

Kevin Gordon The $17 billion merger between Quintiles and IMS Health means more than a new title and responsibilities for Quintiles CEO Tom Pike. One of Quntiles' top executives will leave along with two board members if the deal wins regulatory approval.

July 20, 2016

Premium Lock Number of biotechs likely to use a CRO increasing

Worldwide Clinical Trials A recent survey by Morrisville-baed Worldwide Clinical Trials revealed that 62 percent of respondents are more likely to engage a clinical research organization (CRO) partner for clinical research than they were five years ago. That means business for many NC firms.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith